A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms PATHWAY
  • Sponsors Amgen; MedImmune
  • Most Recent Events

    • 13 Sep 2017 Planned locations also included Poland.
    • 07 Sep 2017 Results published in the New England Journal of Medicine
    • 06 Sep 2017 Results published in an Amgen and AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top